
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hand Dermatoses.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 28, 2024
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ruxolitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lupus Erythematosus, Discoid.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : OpSCF
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : Opsidio, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
Details : OpSCF is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : OpSCF
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Opsidio, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects with Atopic Dermatitis
Details : Triamcinolone Acetonide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2023
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bimekizumab
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : CIUSSS de l'Est-de-l'Île-de-Montréal
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis
Details : Bimekizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Bimekizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : CIUSSS de l'Est-de-l'Île-de-Montréal
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BMX-010
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : BioMimetix JV
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
Details : BMX-010 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : BMX-010
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : BioMimetix JV
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Dermavant Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist,is a non-steroidal topical that is a new chemical entity approved in the US for the topical treatment of plaque psoriasis in adults.
Product Name : Vtama
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 21, 2022
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Dermavant Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Ruxolitinib Cream in Children With Atopic Dermatitis
Details : Ruxolitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 05, 2021
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ifx-1
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Recipient : InflaRx
Deal Size : Inapplicable
Deal Type : Inapplicable
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
Details : Vilobelimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pyoderma Gangrenosum.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 03, 2019
Lead Product(s) : Ifx-1
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Recipient : InflaRx
Deal Size : Inapplicable
Deal Type : Inapplicable
